Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Asgeir Sigurdsson is active.

Publication


Featured researches published by Asgeir Sigurdsson.


Nature | 2008

Large recurrent microdeletions associated with schizophrenia.

Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; T. Sigmundsson; Jacobine E. Buizer-Voskamp; Thomas V O Hansen; Klaus D. Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M. Matthews; Arnaldur Gylfason; Bjarni V. Halldórsson; Daniel F. Gudbjartsson; Thorgeir E. Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Björnsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B. Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette M. Hartmann

Reduced fecundity, associated with severe mental disorders, places negative selection pressure on risk alleles and may explain, in part, why common variants have not been found that confer risk of disorders such as autism, schizophrenia and mental retardation. Thus, rare variants may account for a larger fraction of the overall genetic risk than previously assumed. In contrast to rare single nucleotide mutations, rare copy number variations (CNVs) can be detected using genome-wide single nucleotide polymorphism arrays. This has led to the identification of CNVs associated with mental retardation and autism. In a genome-wide search for CNVs associating with schizophrenia, we used a population-based sample to identify de novo CNVs by analysing 9,878 transmissions from parents to offspring. The 66 de novo CNVs identified were tested for association in a sample of 1,433 schizophrenia cases and 33,250 controls. Three deletions at 1q21.1, 15q11.2 and 15q13.3 showing nominal association with schizophrenia in the first sample (phase I) were followed up in a second sample of 3,285 cases and 7,951 controls (phase II). All three deletions significantly associate with schizophrenia and related psychoses in the combined sample. The identification of these rare, recurrent risk variants, having occurred independently in multiple founders and being subject to negative selection, is important in itself. CNV analysis may also point the way to the identification of additional and more prevalent risk variants in genes and pathways involved in schizophrenia.


Science | 2007

A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction

Anna Helgadottir; Gudmar Thorleifsson; Andrei Manolescu; Solveig Gretarsdottir; Thorarinn Blondal; Aslaug Jonasdottir; Adalbjorg Jonasdottir; Asgeir Sigurdsson; Adam Baker; Arnar Palsson; Gisli Masson; Daniel F. Gudbjartsson; Kristinn P. Magnusson; Karl Andersen; Allan I. Levey; Valgerdur M. Backman; Sigurborg Matthiasdottir; Thorbjorg Jonsdottir; Stefan Palsson; Helga Einarsdottir; Steinunn Gunnarsdottir; Arnaldur Gylfason; Viola Vaccarino; W. Craig Hooper; Muredach P. Reilly; Christopher B. Granger; Harland Austin; Daniel J. Rader; Svati H. Shah; Arshed A. Quyyumi

The global endemic of cardiovascular diseases calls for improved risk assessment and treatment. Here, we describe an association between myocardial infarction (MI) and a common sequence variant on chromosome 9p21. This study included a total of 4587 cases and 12,767 controls. The identified variant, adjacent to the tumor suppressor genes CDKN2A and CDKN2B, was associated with the disease with high significance. Approximately 21% of individuals in the population are homozygous for this variant, and their estimated risk of suffering myocardial infarction is 1.64 times as great as that of noncarriers. The corresponding risk is 2.02 times as great for early-onset cases. The population attributable risk is 21% for MI in general and 31% for early-onset cases.


Nature | 2012

Rate of de novo mutations and the importance of father/'s age to disease risk

Augustine Kong; Michael L. Frigge; Gisli Masson; Søren Besenbacher; Patrick Sulem; Gisli Magnusson; Sigurjon A. Gudjonsson; Asgeir Sigurdsson; Aslaug Jonasdottir; Adalbjorg Jonasdottir; Wendy S. W. Wong; Gunnar Sigurdsson; G. Bragi Walters; Stacy Steinberg; Hannes Helgason; Gudmar Thorleifsson; Daniel F. Gudbjartsson; Agnar Helgason; Olafur T. Magnusson; Unnur Thorsteinsdottir; Kari Stefansson

Mutations generate sequence diversity and provide a substrate for selection. The rate of de novo mutations is therefore of major importance to evolution. We conducted a study of genomewide mutation rate by sequencing the entire genomes of 78 Icelandic parent-offspring trios at high coverage. Here we show that in our samples, with an average father’s age of 29.7, the average de novo mutation rate is 1.20×10−8 per nucleotide per generation. Most strikingly, the diversity in mutation rate of single-nucleotide polymorphism (SNP) is dominated by the age of the father at conception of the child. The effect is an increase of about 2 mutations per year. After accounting for random Poisson variation, father’s age is estimated to explain nearly all of the remaining variation in the de novo mutation counts. These observations shed light on the importance of the father’s age on the risk of diseases such as schizophrenia and autism.


Nature Genetics | 2007

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24

Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel F. Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon Thor Bergthorsson; Bjarni A. Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R. Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N. Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M. Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W. Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C. Walsh; Dorine W. Swinkels; Sebastian Navarrete

Prostate cancer is the most prevalent noncutaneous cancer in males in developed regions, with African American men having among the highest worldwide incidence and mortality rates. Here we report a second genetic variant in the 8q24 region that, in conjunction with another variant we recently discovered, accounts for about 11%–13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans. We made the current discovery through a genome-wide association scan of 1,453 affected Icelandic individuals and 3,064 controls using the Illumina HumanHap300 BeadChip followed by four replication studies. A key step in the discovery was the construction of a 14-SNP haplotype that efficiently tags a relatively uncommon (2%–4%) susceptibility variant in individuals of European descent that happens to be very common (∼42%) in African Americans. The newly identified variant shows a stronger association with affected individuals who have an earlier age at diagnosis.


Nature | 2007

Variants conferring risk of atrial fibrillation on chromosome 4q25.

Daniel F. Gudbjartsson; David O. Arnar; Anna Helgadottir; Solveig Gretarsdottir; Hilma Holm; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Adam Baker; Gudmar Thorleifsson; Kristleifur Kristjansson; Arnar Palsson; Thorarinn Blondal; Patrick Sulem; Valgerdur M. Backman; Gudmundur A. Hardarson; Ebba Palsdottir; Agnar Helgason; Runa Sigurjonsdottir; Jon T. Sverrisson; Konstantinos Kostulas; Maggie C.Y. Ng; Larry Baum; Wing Yee So; Ka Sing Wong; Juliana C.N. Chan; Karen L. Furie; Steven M. Greenberg; Michelle Sale; Peter J. Kelly; Calum A. MacRae

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans and is characterized by chaotic electrical activity of the atria. It affects one in ten individuals over the age of 80 years, causes significant morbidity and is an independent predictor of mortality. Recent studies have provided evidence of a genetic contribution to AF. Mutations in potassium-channel genes have been associated with familial AF but account for only a small fraction of all cases of AF. We have performed a genome-wide association scan, followed by replication studies in three populations of European descent and a Chinese population from Hong Kong and find a strong association between two sequence variants on chromosome 4q25 and AF. Here we show that about 35% of individuals of European descent have at least one of the variants and that the risk of AF increases by 1.72 and 1.39 per copy. The association with the stronger variant is replicated in the Chinese population, where it is carried by 75% of individuals and the risk of AF is increased by 1.42 per copy. A stronger association was observed in individuals with typical atrial flutter. Both variants are adjacent to PITX2, which is known to have a critical function in left–right asymmetry of the heart.


Nature Genetics | 2006

A common variant associated with prostate cancer in European and African populations

Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A. Agnarsson; Asgeir Sigurdsson; Kristrun R. Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N. Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret B. Andresdottir; Olafia Svandis Gretarsdottir; Jon Thor Bergthorsson; Daniel F. Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi J. Ísaksson; Julie A. Douglas

With the increasing incidence of prostate cancer, identifying common genetic variants that confer risk of the disease is important. Here we report such a variant on chromosome 8q24, a region initially identified through a study of Icelandic families. Allele −8 of the microsatellite DG8S737 was associated with prostate cancer in three case-control series of European ancestry from Iceland, Sweden and the US. The estimated odds ratio (OR) of the allele is 1.62 (P = 2.7 × 10−11). About 19% of affected men and 13% of the general population carry at least one copy, yielding a population attributable risk (PAR) of ∼8%. The association was also replicated in an African American case-control group with a similar OR, in which 41% of affected individuals and 30% of the population are carriers. This leads to a greater estimated PAR (16%) that may contribute to higher incidence of prostate cancer in African American men than in men of European ancestry.


Nature Genetics | 2007

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon Thor Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel F. Gudbjartsson; Bjarni A. Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R. Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N. Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T. Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Z. Bagger; Robert L. Wilensky; Muredach P. Reilly; Andrew D. Morris; Charlotte H. Kimber

We performed a genome-wide association scan to search for sequence variants conferring risk of prostate cancer using 1,501 Icelandic men with prostate cancer and 11,290 controls. Follow-up studies involving three additional case-control groups replicated an association of two variants on chromosome 17 with the disease. These two variants, 33 Mb apart, fall within a region previously implicated by family-based linkage studies on prostate cancer. The risks conferred by these variants are moderate individually (allele odds ratio of about 1.20), but because they are common, their joint population attributable risk is substantial. One of the variants is in TCF2 (HNF1β), a gene known to be mutated in individuals with maturity-onset diabetes of the young type 5. Results from eight case-control groups, including one West African and one Chinese, demonstrate that this variant confers protection against type 2 diabetes.


Nature Genetics | 2009

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Thorunn Rafnar; Patrick Sulem; Simon N. Stacey; Frank Geller; Julius Gudmundsson; Asgeir Sigurdsson; Margret Jakobsdottir; Hafdis T. Helgadottir; Steinunn Thorlacius; Katja K. Aben; Thorarinn Blondal; Thorgeir E. Thorgeirsson; Gudmar Thorleifsson; Kristleifur Kristjansson; Kristin Thorisdottir; Rafn Ragnarsson; Bardur Sigurgeirsson; Halla Skuladottir; Tomas Gudbjartsson; Helgi J. Ísaksson; Gudmundur V. Einarsson; Kristrun R. Benediktsdottir; Bjarni A. Agnarsson; Karl Olafsson; Anna Salvarsdottir; Hjordis Bjarnason; Margret Asgeirsdottir; Kari T. Kristinsson; Sigurborg Matthiasdottir; Steinunn G Sveinsdottir

The common sequence variants that have recently been associated with cancer risk are particular to a single cancer type or at most two. Following up on our genome-wide scan of basal cell carcinoma, we found that rs401681[C] on chromosome 5p15.33 satisfied our threshold for genome-wide significance (OR = 1.25, P = 3.7 × 10−12). We tested rs401681 for association with 16 additional cancer types in over 30,000 cancer cases and 45,000 controls and found association with lung cancer (OR = 1.15, P = 7.2 × 10−8) and urinary bladder, prostate and cervix cancer (ORs = 1.07−1.31, all P < 4 × 10−4). However, rs401681[C] seems to confer protection against cutaneous melanoma (OR = 0.88, P = 8.0 × 10−4). Notably, most of these cancer types have a strong environmental component to their risk. Investigation of the region led us to rs2736098[A], which showed stronger association with some cancer types. However, neither variant could fully account for the association of the other. rs2736098 corresponds to A305A in the telomerase reverse transcriptase (TERT) protein and rs401681 is in an intron of the CLPTM1L gene.


Nature | 2009

Parental origin of sequence variants associated with complex diseases.

Augustine Kong; Valgerdur Steinthorsdottir; Gisli Masson; Gudmar Thorleifsson; Patrick Sulem; Søren Besenbacher; Aslaug Jonasdottir; Asgeir Sigurdsson; Kari T. Kristinsson; Adalbjorg Jonasdottir; Michael L. Frigge; Arnaldur Gylfason; Pall Olason; Sigurjon A. Gudjonsson; Sverrir Sverrisson; Simon N. Stacey; Bardur Sigurgeirsson; Kristrun R. Benediktsdottir; Helgi Sigurdsson; Thorvaldur Jonsson; Rafn Benediktsson; Jón Ólafsson; Oskar Th Johannsson; Astradur B. Hreidarsson; Gunnar Sigurdsson; Anne C. Ferguson-Smith; Daniel F. Gudbjartsson; Unnur Thorsteinsdottir; Kari Stefansson

Effects of susceptibility variants may depend on from which parent they are inherited. Although many associations between sequence variants and human traits have been discovered through genome-wide associations, the impact of parental origin has largely been ignored. Here we show that for 38,167 Icelanders genotyped using single nucleotide polymorphism (SNP) chips, the parental origin of most alleles can be determined. For this we used a combination of genealogy and long-range phasing. We then focused on SNPs that associate with diseases and are within 500 kilobases of known imprinted genes. Seven independent SNP associations were examined. Five—one with breast cancer, one with basal-cell carcinoma and three with type 2 diabetes—have parental-origin-specific associations. These variants are located in two genomic regions, 11p15 and 7q32, each harbouring a cluster of imprinted genes. Furthermore, we observed a novel association between the SNP rs2334499 at 11p15 and type 2 diabetes. Here the allele that confers risk when paternally inherited is protective when maternally transmitted. We identified a differentially methylated CTCF-binding site at 11p15 and demonstrated correlation of rs2334499 with decreased methylation of that site.


Nature Genetics | 2008

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.

Simon N. Stacey; Andrei Manolescu; Patrick Sulem; Steinunn Thorlacius; Sigurjon A. Gudjonsson; Gudbjorn F. Jonsson; Margret Jakobsdottir; Jon Thor Bergthorsson; Julius Gudmundsson; Katja K. Aben; Luc J Strobbe; Dorine W. Swinkels; K. C.Anton van Engelenburg; Brian E. Henderson; Laurence N. Kolonel; Loic Le Marchand; Esther Millastre; Raquel Andres; Berta Saez; Julio Lambea; Javier Godino; Eduardo Polo; Alejandro Tres; Simone Picelli; Johanna Rantala; Sara Margolin; Thorvaldur Jonsson; Helgi Sigurdsson; Thora Jonsdottir; Jón Hrafnkelsson

We carried out a genome-wide association study of breast cancer predisposition with replication and refinement studies involving 6,145 cases and 33,016 controls and identified two SNPs (rs4415084 and rs10941679) on 5p12 that confer risk, preferentially for estrogen receptor (ER)-positive tumors (OR = 1.27, P = 2.5 × 10−12 for rs10941679). The nearest gene, MRPS30, was previously implicated in apoptosis, ER-positive tumors and favorable prognosis. A recently reported signal in FGFR2 was also found to associate specifically with ER-positive breast cancer.

Collaboration


Dive into the Asgeir Sigurdsson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge